Application Status and Rationality Analysis of Chinese Patent Medicines Containing Borneol in 6674 Inpatients
Objective:To analyze the current status and rationality of clinical use of Chinese patent medicines containing borneol,so as to provide reference for standardizing its clinical application.Methods:The medical records of inpatients with borneol prescription from January 2022 to May 2023 in a hospital information system were retrieved to summarize basic information,clinical diagnosis,drug selection,repeat/combination medications,course of treatment,etc.Descriptive statistics were used to perform retrospective analysis and evaluate the rationality of medical orders.Results:There were 11 Chinese patent medicines containing borneol prescribed in inpatient dispensary and all of them were oral dosage form.Chinese patent medicines containing borneol were used by 6674 patients for 8050 cases,with compound Danshen dripping pills as the most frequently used medication which was used for 1513 cases(18.80%).In the aspect of irrational drug use,inappropriate course of treatment was identified in 793 cases(11.88%),inappropriate repeat/combination medications in 199 cases(2.98%),incomplete records of clinical diagnosis in 70 cases(1.05%),and inappropriate drug selection in 8 cases(0.12%).No adverse drug reactions were observed in the patients.Conclusion:The clinical use of Chinese patent medicines containing borneol is partly irrational in terms of course of treatment,dosage and repeat/combination medications,and therefore relevant supervision and management need strengthening to ensure the safety and efficacy of drug use.
borneolChinese patent medicineapplication statusrational drug usecomments on medical orders
万方数据
维普
